|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
585,690,000 |
Market
Cap: |
178.65(B) |
Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
52
Week Range: |
$217.36 - $324.56 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 499 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
Total People Sold |
1 |
1 |
3 |
6 |
Total Sell Transactions |
1 |
1 |
4 |
8 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Grygiel Nancy A. |
SVP & CCO |
|
2021-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,245 |
12,401 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2021-02-18 |
4 |
D |
$235.61 |
$11,197,836 |
D/D |
(47,527) |
570,853 |
|
- |
|
Bradway Robert A |
Chairman, CEO and President |
|
2021-02-18 |
4 |
OE |
$54.69 |
$4,019,715 |
D/D |
73,500 |
618,380 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-02-16 |
4 |
D |
$237.21 |
$272,080 |
D/D |
(1,147) |
40,912 |
|
- |
|
Reese David M |
EVP, Research and Development |
|
2021-02-16 |
4 |
OE |
$54.69 |
$125,787 |
D/D |
2,300 |
42,059 |
|
- |
|
Sugar Ronald D |
Director |
|
2021-02-10 |
4 |
AS |
$238.40 |
$238,400 |
D/D |
(1,000) |
15,805 |
|
1% |
|
Sugar Ronald D |
Director |
|
2021-02-10 |
4 |
OE |
$71.64 |
$71,640 |
D/D |
1,000 |
16,805 |
|
- |
|
Williams R Sanders |
Director |
|
2021-02-08 |
4 |
AS |
$237.99 |
$59,498 |
D/D |
(250) |
4,659 |
|
0% |
|
Johnston Lori A |
EVP, HR |
|
2021-02-07 |
4 |
D |
$236.32 |
$112,016 |
D/D |
(474) |
32,074 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
17 |
6,908 |
|
- |
|
Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
|
2021-02-04 |
4 |
S |
$236.51 |
$2,627,625 |
D/D |
(11,110) |
39,945 |
|
-1% |
|
Sugar Ronald D |
Director |
|
2021-01-13 |
4 |
AS |
$235.99 |
$235,990 |
D/D |
(1,000) |
15,805 |
|
2% |
|
Sugar Ronald D |
Director |
|
2021-01-13 |
4 |
OE |
$71.64 |
$71,640 |
D/D |
1,000 |
16,805 |
|
- |
|
Williams R Sanders |
Director |
|
2020-11-09 |
4 |
AS |
$242.40 |
$60,600 |
D/D |
(250) |
4,909 |
|
6% |
|
Reese David M |
EVP, Research and Development |
|
2020-11-02 |
4 |
D |
$216.94 |
$460,998 |
D/D |
(2,125) |
39,619 |
|
- |
|
Louie Linda H. |
VP, Finance & CAO |
|
2020-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,453 |
7,632 |
|
- |
|
Gordon Murdo |
EVP Global Commercial Ops |
|
2020-11-02 |
4 |
D |
$216.94 |
$1,359,997 |
D/D |
(6,269) |
32,036 |
|
- |
|
Kullman Ellen Jamison |
Director |
|
2020-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
141 |
6,846 |
|
- |
|
Sugar Ronald D |
Director |
|
2020-08-19 |
4 |
AS |
$241.02 |
$241,020 |
D/D |
(1,000) |
15,589 |
|
-4% |
|
Sugar Ronald D |
Director |
|
2020-08-19 |
4 |
OE |
$54.69 |
$54,690 |
D/D |
1,000 |
16,589 |
|
- |
|
Williams R Sanders |
Director |
|
2020-08-07 |
4 |
AS |
$242.95 |
$60,738 |
D/D |
(250) |
5,159 |
|
-5% |
|
Grygiel Nancy A. |
SVP & CCO |
|
2020-08-03 |
4 |
D |
$244.67 |
$70,954 |
D/D |
(290) |
11,026 |
|
- |
|
Santos Esteban |
EVP, Operations |
|
2020-08-01 |
4 |
D |
$244.67 |
$529,711 |
D/D |
(2,165) |
44,376 |
|
- |
|
Miles Amy E |
Director |
|
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
408 |
408 |
|
- |
|
Grygiel Nancy A. |
SVP & CCO |
|
2020-07-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,174 |
11,316 |
|
- |
|
2206 Records found
|
|
Page 15 of 89 |
|
|